Edgewise Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Edgewise Therapeutics, Inc. (EWTX) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of -$177.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-26
- Edgewise Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was -$177.00K, a 143.70% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $405.00K, a 2282.35% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $17.00K.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month |
|---|---|
| 2025-12-31 | -$177.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | $405.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | $17.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |